I’ve been on compounded tirzepatide since Dec 2024 and I’m prepared to be on micro doses for life simply because of the normalization of all my blood and inflammation markers., let alone the fact that I feel amazing.
Ideally a drug has clinical trials that show improvements in health outcomes such as heart disease or mortality instead of surrogate markers for health such as cholesterol, weight, and inflammation.
While we all expect that if we see improvements in surrogate markers, we probably are improving health outcomes, still biology can be surprising, so we prefer the studies that show actual health improvements.
For the moment, I think Semaglutide may be the only drug that has demonstrated improvements in health outcomes in the heart disease space, and I think the FDA gave them a formal approval for use in heart disease. I think that means that cardiologists can prescribe Semaglutide on-label for heart disease, whereas Tirzepatide would be off-label for heart disease. (I think!)
This on-label / off-label stuff can be important when it comes to insurance coverage. So it is important from a patient perspective.
Anyway, I am not an expert and I might have made errors in this comment. I welcome correction. Best wishes to all!
I’ve been on compounded tirzepatide since Dec 2024 and I’m prepared to be on micro doses for life simply because of the normalization of all my blood and inflammation markers., let alone the fact that I feel amazing.
Yes yes yes! Let’s see the insurance companies continue to deny that we need treatment!
Ideally a drug has clinical trials that show improvements in health outcomes such as heart disease or mortality instead of surrogate markers for health such as cholesterol, weight, and inflammation.
While we all expect that if we see improvements in surrogate markers, we probably are improving health outcomes, still biology can be surprising, so we prefer the studies that show actual health improvements.
For the moment, I think Semaglutide may be the only drug that has demonstrated improvements in health outcomes in the heart disease space, and I think the FDA gave them a formal approval for use in heart disease. I think that means that cardiologists can prescribe Semaglutide on-label for heart disease, whereas Tirzepatide would be off-label for heart disease. (I think!)
This on-label / off-label stuff can be important when it comes to insurance coverage. So it is important from a patient perspective.
Anyway, I am not an expert and I might have made errors in this comment. I welcome correction. Best wishes to all!
Great assessment, I hope others think the same way so as to offer broader support to more patients.
Wonderful and Hopeful news !!